PMID- 18671911
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20181201
IS  - 0393-5264 (Print)
IS  - 0393-5264 (Linking)
VI  - 23
IP  - 2
DP  - 2008 Apr-Jun
TI  - Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum 
      concentrations and concomitant antiepileptic therapy.
PG  - 97-100
AB  - The aim of this study was to investigate the relationships between oxcarbazepine 
      (OXC) dosage, metabolite mono-hydroxy-derivative (MHD) serum concentrations, 
      number of concomitant antiepileptic drugs, age and incidence of adverse events 
      (AEs) in epileptic patients. A retrospective analysis was conducted of 414 
      consecutive epileptic patients on OXC alone or added-on to previous therapy. The 
      sample was collected from the period 2001 to 2006. Statistical analysis was 
      performed in two groups: with and without AEs. Eighty-seven patients (21%) 
      experienced at least one AE. The most frequent was hyponatremia, reported in 
      9.2%. OXC was discontinued because of AEs in 27 cases. There were no important 
      differences between patients with and without AEs, except for age (p=0.04). The 
      categorization of patients into three different age ranges, <20, 20-59 and (3)60 
      years, disclosed that the risk of AEs is notably lower in young (<20 years) and 
      adult (20-59 years) patients (OR 0.46 and 0.51, respectively). In particular, the 
      patients who experienced hyponatremia were significantly older than those who did 
      not (p=0.0045). The other variables showed no major changes according to age. The 
      incidence of major AEs during OXC treatment, leading to withdrawal, was found to 
      be low and influenced by age, but not by OXC dosage, MHD concentrations or number 
      of concomitant antiepileptic drugs.
FAU - Ortenzi, Andrea
AU  - Ortenzi A
AD  - Regional Epilepsy Centre, Neurological Clinic, Ospedali Riuniti, Ancona, Italy. 
      c.epilessia@ospedaliriuniti.marche.it
FAU - Paggi, Aldo
AU  - Paggi A
FAU - Foschi, Nicoletta
AU  - Foschi N
FAU - Sabbatini, Debirah
AU  - Sabbatini D
FAU - Pistoli, Emore
AU  - Pistoli E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Funct Neurol
JT  - Functional neurology
JID - 8707746
RN  - 0 (Anticonvulsants)
RN  - 33CM23913M (Carbamazepine)
RN  - VZI5B1W380 (Oxcarbazepine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticonvulsants/*adverse effects/blood
MH  - Carbamazepine/adverse effects/*analogs & derivatives/blood
MH  - Child
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - Epilepsy/blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Hyponatremia/*chemically induced
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Oxcarbazepine
MH  - Retrospective Studies
EDAT- 2008/08/02 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/08/02 09:00
PHST- 2008/08/02 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/08/02 09:00 [entrez]
AID - 2955 [pii]
PST - ppublish
SO  - Funct Neurol. 2008 Apr-Jun;23(2):97-100.